"LOTEMAX SM is the culmination of our clinical experience with the loteprednol etabonate compound for more than two decades. We are extremely proud to make this new treatment option available, our ...

The FINANCIAL — MADISON, NJ—Bausch + Lomb, the global eye health company, has added a new product to its signature loteprednol etabonate line: LOTEMAX® Ointment. LOTEMAX Ointment is indicated to treat ...

Bausch + Lomb has announced it has received FDA approval of the company’s new drug application for LOTEMAX 0.5 percent gel drop formulation, according to a news release. The LOTEMAX (loteprednol ...

Please provide your email address to receive an email when new articles are posted on . With four new steroid options on the market to treat pain and inflammation after ocular surgery, ...

Lupin has received approval from the Food and Drug Administration for loteprednol etabonate ophthalmic gel, 0.38%, which is the generic of Bausch & Lomb’s Lotemax SM Ophthalmic Gel. Lupin is the ...

Loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) from Bausch & Lomb was found to have no meaningful impact on intraocular pressure or visual acuity when administered to patients post surgery, ...

Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery. Lotemax SM ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has begun distributing Lotemax SM, its gel drop formulation for the treatment of postoperative ...